🇺🇸 FDA
Pipeline program

Recombinant human Arylsulfatase A (rhASA)

HGT-MLD-048

Phase 2 mab completed

Quick answer

Recombinant human Arylsulfatase A (rhASA) for Late Infantile Metachromatic Leukodystrophy is a Phase 2 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Late Infantile Metachromatic Leukodystrophy
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials